CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Nitric OxideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug107 Acalabrutinib Wiki 0.35
drug923 Favipiravir Wiki 0.12
drug1822 Placebo Wiki 0.03

Correlated MeSH Terms (11)

Name (Synonyms) Correlation
D053120 Respiratory Aspiration NIH 0.19
D004417 Dyspnea NIH 0.19
D011024 Pneumonia, Viral NIH 0.13
D045169 Severe Acute Respiratory Syndrome NIH 0.08
D018352 Coronavirus Infections NIH 0.06
D055371 Acute Lung Injury NIH 0.05
D012127 Respiratory Distress Syndrome, Newborn NIH 0.05
D012128 Respiratory Distress Syndrome, Adult NIH 0.04
D003141 Communicable Diseases NIH 0.04
D011014 Pneumonia NIH 0.03
D007239 Infection NIH 0.03

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0002098 Respiratory distress HPO 0.19
HP:0002090 Pneumonia HPO 0.03

There are 4 clinical trials

Clinical Trials

1 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

NCT04290858 Coronavirus Infections Pneumonia, Viral Dyspnea Drug: Nitric Oxide
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress

Primary Outcomes

Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

Measure: Reduction in the incidence of intubation and mechanical ventilation

Time: 28 days

Secondary Outcomes

Description: Mortality from all causes

Measure: Mortality

Time: 28 days

Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab

Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract

Time: 7 days

Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).

Measure: Time to clinical recovery

Time: 28 days

2 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on SARS-CoV-2 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

NCT04305457 Coronavirus Infections Pneumonia, Viral Acute Respiratory Distress Syndrome Drug: Nitric Oxide
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Description: The primary outcome will be the reduction in the incidence of patients requiring intubation and mechanical ventilation, as a marker of deterioration from a mild to a severe form of COVID-19. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

Measure: Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation

Time: 28 days

Secondary Outcomes

Description: Proportion of deaths from all causes

Measure: Mortality

Time: 28 days

Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air), alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent) and resolution of hypoxia (defined as SpO2 ≥ 93% in room air or P/F ≥ 300 mmHg). All these improvements must be sustained for 72 hours.

Measure: Time to clinical recovery

Time: 28 days

Other Outcomes

Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or oropharyngeal swab.

Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract

Time: 7 days

3 Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19

Novel therapies are desperately needed for treatment of COVID-19 patients. At present, there are no proven interventions to prevent progression of the disease or to rapidly treat patients with COVID-19 related respiratory failure. Data on the original coronavirus -SARS pneumonia suggested that high dose (>160ppm) inhaled Nitric Oxide could have beneficial effects also on COVID-19, due to the genomic similarities between these two coronaviruses (1-3). This study will test whether high dose inhaled nitric oxide is safe and can reverse virus burden and respiratory failure in patients on mechanical ventilation.

NCT04383002 COVID-19 Drug: Nitric Oxide

Primary Outcomes

Measure: COVID-19 PCR status at completion of treatment (day 7) from tracheal aspirate

Time: 7 days

4 Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.

This is a pilot randomized-controlled (2:1) open label investigation of inhaled NO to prevent progression to more advanced disease in 42 hospitalized patients with COVID-19, at risk for worsening, based on baseline systemic oxygenation and 2 or more of the major risk factors of age > 60 years, type II DM, hypertension, and obesity.

NCT04388683 COVID-19 Drug: Nitric Oxide
MeSH:Respiratory Aspiration

Primary Outcomes

Description: Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale (See statistical methods). Between-group differences in the average maximum disease severity assessed through 28 days, through the following severity scores: a) increased liter oxygen flow, through a high flow nasal cannula; b) non-invasive ventilation; c) intubation or institution of ECMO; or d) death.

Measure: Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.

Time: 28 days

Secondary Outcomes

Measure: Prevention of progression assessed by an alternate severity scale

Time: 28 days

Measure: Time to reaching maximal severity score

Time: 28 days

Measure: Proportion of patients in each stage at maximum severity

Time: 28 days

Measure: PaO2/FIO2 or SaO2/FIO2 ratio, measured daily

Time: 28 days

Measure: Length of hospital Stay (death assigned as worst case)

Time: 28 days

Measure: Frequency of Intubation, ECMO, or need to intubate with "Do Not Resuscitate" order

Time: 28 days

Measure: Mortality

Time: 28 days

Measure: IL6 level

Time: 7 days

Measure: TNF-alpha level

Time: 7 days

Measure: Fibrinogen level

Time: 7 days

Measure: CRP level

Time: 7 days

Measure: Ferritin Level

Time: 7 days

Measure: D-dimer level

Time: 7 days

Related HPO nodes (Using clinical trials)

HP:0002094: Dyspnea
Genes 466
RSPH1 PFN1 NKX2-1 SPAG1 ATRX PRRX1 TSC2 RPS28 SH2B3 STAT5B LGI4 DNAH1 UBE3B PON1 DPM2 PRKAR1A COL2A1 GATA6 SFTPC RRM2B PPARGC1A DNAAF1 TRAK1 LTBP3 MAPT DNAH9 FAM13A STN1 ORC6 TRPM4 HCCS RUNX2 GLA DBH DNA2 TERT RSPH4A CCR6 TNNT2 GAS8 AK9 MEGF10 SLC5A7 ACVRL1 COLQ FGFR1 HLA-B CCDC65 RUNX1 BCOR ORC6 SERPINA1 MYH11 SCO2 NDUFS2 NEK1 SETBP1 IRF2BP2 ALAS2 MYBPC3 SCN4A VPS33A GNAS OPTN COL13A1 GBA OTX2 C9ORF72 SCNN1A UNC13A CSF2RB CHRNE ACADVL COX8A SFTPC ABCG8 SFTPB MARS1 NOD2 NUMA1 COL2A1 MAPT LAMB3 FOXF1 COL13A1 ERBB4 SCN5A UBQLN2 GALC DNAAF6 SFTPA2 JPH2 KAT6A CCDC103 SQSTM1 SPP1 SOX9 SSR4 DNAAF4 PLEC FGFR2 TNNI3 NPM1 ATP11A SCNN1B EDN1 ND5 CSPP1 MUC5B NAGS MYH11 CCNF EFEMP2 MYO9A IRF5 FOXJ1 AGRN LDLR WIPF1 COX6B1 MMAA SNAP25 TSC1 CAV1 SRP54 SMAD3 COX14 DCTN1 EP300 DNAL1 NEB TREM2 CAV1 NABP1 PNKD TERC ELN PYGM SFTPC STAT4 HLA-DRB1 WAS FLNC GMNN CASR RSPH9 NEFH COA3 GATA4 SOD1 EFTUD2 TRMT5 ITGA3 MGME1 TNNC1 VCP LAMC2 TARDBP FBN1 TBL1XR1 MRPL3 TGFBR1 MYPN MYL2 CREBBP DSC2 ZFPM2 COL1A2 SLC25A1 ACADM HBB LRP4 IRAK1 SCO2 EPOR SCN1B DNAJB6 DNAI1 DPM1 BMPER DNAJB13 GAA FBP1 ETFDH PARN STX16 CHMP2B FOXP3 CFAP410 GATA6 SLC25A3 TRNL1 POMT1 ADAMTS13 ND3 CPT2 SLC18A3 CHRND CDC45 NR2F2 TRNW NKX2-1 SCNN1G CDC6 TGFBR2 ND6 SLC52A3 FGFR2 MYLK LRRC6 RPS26 DNAAF5 CCNO NDUFAF3 COX20 CFTR TTN DNA2 USP9X NGLY1 XYLT1 MGME1 CYB5R3 LRRC56 EPHA4 MMUT SYT2 LAMB2 TERT PMM2 DNAAF3 SLC25A4 FLNC STT3B DPP9 CHRNA1 BMPR2 ASAH1 AIFM1 EOMES CRELD1 CYB5R3 JAK2 CBL SCO1 KLHL7 VAMP1 ALDH7A1 MCIDAS PGM1 DAO SCN4A NAGS NDUFB8 TACO1 TRNE LYRM4 PON2 SURF1 COX7B COL2A1 CFAP221 PET100 LAMA3 CHRNB1 PML PIGT RPGR STK36 EDA HNRNPA1 HLCS DSP IFT52 FBLN5 NPPA OFD1 APOB PRKCSH COL2A1 CHRNE NME8 FUS ND1 SIK1 ADNP STT3B GLE1 TGFB2 ADCY6 COX10 CFAP298 SMPD1 MATR3 CFAP300 BTNL2 PON3 SLC25A1 HLA-DRB1 RAPSN SPEF2 AIMP2 ACTA2 SCN5A ZBTB16 ZMYND10 SMAD4 COA8 GNAS PRKG1 COQ7 TRIP11 MUSK GLT8D1 ATP6 CCDC39 ARMC4 ABCA3 TRMU CYB5A PRRX1 IKZF1 GNAI3 DNAI2 ORC1 RARA NEK10 SFTPA1 ZIC3 ANXA11 POLG LIFR SLC2A10 GTPBP3 DMPK DOK7 POLG2 MYL3 RTEL1 PCSK9 TAF15 CSF2RA FGFR2 CHAT KCNJ6 FIP1L1 ISCU ASXL1 SERPING1 ETFA ATXN2 DYNC2LI1 TRNK TRNN FBP1 TBX4 TSC2 CHRNA1 COA8 SBDS SLC12A3 VPS33A SFTPA2 TWNK MMUT COPA PLCB4 STAT5B ETFB ENG TRNS1 GBA GAS2L2 PRKAR1A SCN4A FGFR2 VCP BMPER TET2 CCDC151 MFAP5 TRPV6 TBK1 NUP214 MMAB DNASE1L3 SLC35A1 CLCNKB TK2 LOX RNU4ATAC TET2 FAM20C LDLRAP1 IFT81 CHRNB1 DISC1 TGFB3 ERF FIG4 STAT3 MUC5B CHRNE EPHB4 PRPH DNAH5 GBA PUF60 BTNL2 TTC12 ORC4 TUBB4A ABCG5 ARX CRLF1 SDCCAG8 GYG1 CHCHD10 TBC1D24 ORC1 EIF2AK4 MPC1 CHRND SRSF2 CCDC40 CSF2RB ND4 ANG CHAT TSC1 VAPB NKX2-5 DNAAF3 TTC25 VCL DNAAF2 TRNK DPM2 DRC1 PRRT2 ND2 TRNE IL1RN RSPH3 DNAJC21 KIF20A USP9X HLA-DRB1 TRNV PSAP HYDIN KCNA1 CDT1 CCDC114 MAT2A ABCA3 GATA6 NDUFB11 CNTNAP1 FOXE3 CCN2 GNAS AGRN TRIP11 TET2 DNAH11
Protein Mutations 0
SNP 0
HP:0002090: Pneumonia
Genes 220
KMT2D OSTM1 GBA RSPH1 DOCK8 NKX2-1 RNU4ATAC SPAG1 RAG1 MCIDAS AFF4 TNFRSF13C DNAH1 NOTCH3 CD19 ALMS1 NADK2 UNC119 SFTPC FOXN1 CD79B CFAP221 CD81 SAMD9 MED25 ZAP70 RAG2 IGLL1 DNAAF1 RPGR STK36 LTBP3 PLOD1 DNAH9 BTK TERT COL11A2 OFD1 TNFRSF11A LRBA RSPH4A CD19 NME8 SMARCD2 GAS8 CFTR TNFRSF13B CCDC65 CFAP298 COL11A2 RAG1 ORC6 P4HTM MAN2B1 CFAP300 JAK3 CACNA1C ICOS SETBP1 TNFRSF13C SPEF2 LIG4 NIPBL STAT3 ZMYND10 IL7R MAN2B1 HLA-DQA1 IL21R SELENON SP110 ACADVL CCDC39 ARMC4 NSMCE3 NFIX DNAI2 ACP5 PTPRC ZAP70 KIAA0586 FCGR2A NFKB2 NEK10 MTHFD1 EGFR RYR1 ADA DNAI1 TGFB1 DNAAF6 IL2RG KCNJ6 DCLRE1C CCDC103 IGHM GNPTAB DNAAF4 PNP CFB DCLRE1C TAF1 CARD11 USB1 ADA ICOS FMO3 IL2RG HLA-DQB1 GFI1 SFTPA2 ICOS CD3D FOXJ1 CRLF1 ELANE IL2RG SRP54 NFKB1 PANK2 GAS2L2 CD247 IRF8 GAS8 RAG2 CCDC151 WAS ZBTB24 CD3E DNAL1 EXTL3 SLC35A1 NCF1 TK2 MS4A1 IFNGR1 RNF168 RMRP RSPH9 NHLRC1 MUC5B TNFRSF13C DNAH5 DNMT3B RNF125 EPM2A TTC12 JAK3 LEP RAC1 CYBA PGM3 NOS1 DDR2 AFF4 TBC1D24 CHD7 TNFRSF13B OFD1 DNAI1 RANBP2 TCIRG1 DNAJB13 CR2 CCDC40 IL2RG NCF2 RAG2 SLC25A24 SGCG WDR19 FOXP3 RNU4ATAC ACTA1 UBB CFAP410 BTK TTC25 CARD11 DNAAF2 CXCR4 MASP2 DRC1 TBCD DCLRE1C CYBB RSPH3 LRRC6 PIGN TNFSF12 DNAAF5 CCNO CSPP1 CR2 SLC35C1 HYDIN TIMM8A NBN NFKB2 CCDC114 CASP8 ADA IL7R CCDC114 TNFSF12 BTK LRRC56 PEPD BLNK CD55 GRHL3 NBN PRKCD KPTN PMM2 DNAAF3 KDM6A POLA1 RAG1 DNAH11
Protein Mutations 6
A2063G G551D K55R L460D R287Q S1009A
SNP 0
HP:0002098: Respiratory distress
Genes 233
RSPH1 NKX2-1 SCO1 SPAG1 KLHL7 VAMP1 ALDH7A1 PRRX1 TSC2 MCIDAS RPS28 NAGS NDUFB8 LGI4 DNAH1 TACO1 TRNE LYRM4 UBE3B DPM2 SURF1 COL2A1 COX7B COL2A1 CFAP221 PET100 DNAAF1 TRAK1 RPGR STK36 EDA MAPT HLCS DNAH9 ORC6 HCCS RUNX2 IFT52 FBLN5 OFD1 RSPH4A COL2A1 CHRNE NME8 GAS8 MEGF10 SLC5A7 ND1 SIK1 ADNP STT3B COLQ ADCY6 COX10 FGFR1 CCDC65 CFAP298 CFAP300 SCO2 NDUFS2 SETBP1 SPEF2 AIMP2 VPS33A COL13A1 ZMYND10 COA8 OTX2 COQ7 TRIP11 CSF2RB ACADVL ATP6 COX8A CCDC39 ARMC4 TRMU SFTPB PRRX1 GNAI3 DNAI2 ORC1 COL2A1 NEK10 ZIC3 LIFR MAPT SLC2A10 DMPK FOXF1 GALC DNAAF6 CSF2RA FGFR2 CHAT KAT6A CCDC103 SERPING1 ETFA SOX9 SSR4 DNAAF4 FGFR2 DYNC2LI1 TRNN FBP1 EDN1 ND5 SBDS SLC12A3 NAGS EFEMP2 VPS33A MYO9A MMUT COPA PLCB4 STAT5B FOXJ1 AGRN ETFB COX6B1 MMAA SNAP25 TRNS1 GBA GAS2L2 SRP54 FGFR2 BMPER COX14 CCDC151 TRPV6 EP300 NUP214 DNAL1 MMAB SLC35A1 CLCNKB TK2 SFTPC FAM20C IFT81 GMNN RSPH9 COA3 DISC1 EFTUD2 ERF ITGA3 EPHB4 DNAH5 GBA PUF60 TTC12 CREBBP ORC4 TUBB4A ZFPM2 SDCCAG8 SLC25A1 TBC1D24 SCO2 ORC1 MPC1 DNAI1 DPM1 BMPER DNAJB13 CCDC40 ETFDH ND4 CHAT TSC1 FOXP3 GATA6 SLC25A3 TRNL1 POMT1 ADAMTS13 DNAAF3 TTC25 ND3 DNAAF2 CPT2 SLC18A3 TRNK CDC45 DPM2 TRNW NKX2-1 CDC6 DRC1 ND6 SLC52A3 ND2 FGFR2 TRNE IL1RN RSPH3 LRRC6 RPS26 DNAJC21 DNAAF5 CCNO NDUFAF3 COX20 USP9X USP9X TRNV PSAP HYDIN NGLY1 XYLT1 KCNA1 CDT1 CCDC114 LRRC56 ABCA3 GATA6 NDUFB11 MMUT SYT2 LAMB2 PMM2 CNTNAP1 DNAAF3 STT3B TRIP11 ASAH1 AIFM1 EOMES DNAH11
Protein Mutations 1
A118G
SNP 1
rs7103572